The stock's fall snapped a three-day winning streak.

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" ...

AbbVie’s projected 2025 earnings just got trimmed by Cantor Fitzgerald, slicing estimates from $12.31 per share to $11.84.

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Glenmark's arm IGI Therapeutics signs a $700 million licensing deal with AbbVie for its cancer drug ISB 2001, with potential ...

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1) ...

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

Global immunotherapy drugs market is valued at approximately USD 247.44 billion in 2023 and is projected to grow at a healthy CAGR of 15.3% over the forecast period 2024-2032. Request To Download Free ...

Total aggregate value of the drugs generating the highest sales in 2024 rose 6.5% vs. 2023, and jumped 53% over five years.